Abstract
Assessment of overall survival obtained from the real-world study of using the combination of palbociclib with aromatase inhibitors as a first-line treatment of HR+/HER2− metastatic breast cancer
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
